Bristol-Myers Squibb Co. (BMY) has seen noteworthy market activity, marked by both rises and falls. A couple of drivers contributing to this activity include the CHMP positive opinion for Opdivo in multiple solid tumors as well as the EMA Panel Approval recommendation for the same drug. Additionally, Jim Cramer has highlighted a 'Multi-Billionaire Dollar' catalyst for the company. Reports indicate that the interest in Sotyktu is increasing despite a 3% dip in share price. There's also noteworthy news about BMY receiving a positive opinion for neoadjuvant Opdivo and chemotherapy. However, the company's planning of cutting $2 billion costs by 2027 alongside weak guidance has generated concerns. A significant development is the company's plan to acquire 2seventy bio. The FDA has also approved Bristol Myers Squibb’s COBENFY (xanomeline and trospium chloride), a novel therapeutic for schizophrenia treatment in adults, and Opdivo Qvantig. Despite some stock dips and criticism over a weak outlook, the company's financial stability and enduring interest from institutional investors suggest Bristol-Myers Squibb’s long-term outlook as a potential strong investment choice.
Bristol-Myers Squibb BMY News Analytics from Tue, 06 Aug 2024 07:00:00 GMT to Sat, 29 Mar 2025 13:41:15 GMT -
Rating 7
- Innovation 5
- Rumor 2
